Opening Day: Scribe Therapeutics makes strong trading debut
Scribe Therapeutics makes its public debut above issue price as the CRISPR drug developer opened for trading last week. The biotech entered the market with cardiometabolic programs at the forefront and early momentum behind its platform story. LATEST IPOS AND DIRECT LISTINGS: Scribe Therapeutics (SCTX) opened on July 2